TCIM
AGRX

TIAA CREF Investment Management’s Agile Therapeutics AGRX Stock Holding History

TIAA CREF Investment Management’s Portfolio AGRX Stock Details AGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-20
Closed -$128K – 3198
2017
Q1 		$128K Hold
20
– – ﹤0.01% 3029
2016
Q4 		$228K Sell
20
-1
-5% -$14K ﹤0.01% 3026
2016
Q3 		$287K Buy
21
+1
+5% +$14.3K ﹤0.01% 3005
2016
Q2 		$301K Buy
20
+4
+25% +$54.8K ﹤0.01% 3032
2016
Q1 		$202K Hold
16
– – ﹤0.01% 2974
2015
Q4 		$318K Hold
16
– – ﹤0.01% 3005
2015
Q3 		$220K Sell
16
-6
-27% -$107K ﹤0.01% 3032
2015
Q2 		$383K Buy
+22
New +$469K ﹤0.01% 3025

Other funds holding AGRX

PAI
ProQuest Associates IV Naples, Florida $53M AUM 3.35% 1-Year Est. Return
IA
Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
CC
Caxton Corporation Princeton, New Jersey $1.85M AUM 176.16% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
RA
Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

TIAA CREF Investment Management's AGRX Position: Q2 2017 in Review

TIAA CREF Investment Management sold out of Agile Therapeutics (AGRX) in Q2 2017, closing a stake of 20 shares — an estimated $128K sold.

TIAA CREF Investment Management first reported a position in AGRX in Q2 2015 and held it in 8 quarters. The position peaked at $383K in Q2 2015. 41 funds tracked by Wall St. Rank hold AGRX as of Q2 2017.

  • TIAA CREF Investment Management reported no remaining Agile Therapeutics position as of Q2 2017 after selling out during the quarter.
  • TIAA CREF Investment Management sold 20 Agile Therapeutics shares in Q2 2017, an estimated $128K.
  • TIAA CREF Investment Management first reported a position in Agile Therapeutics in Q2 2015 and held it in 8 quarters.
  • TIAA CREF Investment Management's Agile Therapeutics position peaked at $383K in Q2 2015.
  • 41 funds tracked by Wall St. Rank held Agile Therapeutics as of Q2 2017.

Based on TIAA CREF Investment Management's 13F filing for Q2 2017, filed 10 Aug 2017.